Cargando…

PARP Inhibition by Flavonoids Induced Selective Cell Killing to BRCA2-Deficient Cells

High consumption of dietary flavonoids might contribute to a reduction of cancer risks. Quercetin and its glycosides have PARP inhibitory effects and can induce selective cytotoxicity in BRCA2-deficient cells by synthetic lethality. We hypothesized that common flavonoids in diet naringenin, hesperet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Cathy, Haskins, Alexis H., Omata, Chisato, Aizawa, Yasushi, Kato, Takamitsu A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5748637/ https://www.ncbi.nlm.nih.gov/pubmed/29023372 http://dx.doi.org/10.3390/ph10040080

Ejemplares similares

Hypersensitivity of BRCA2 deficient cells to rosemary extract explained by weak PARP inhibitory activity
por: Su, Cathy, et al.
Publicado: (2017)

Natural and glucosyl flavonoids inhibit poly(ADP-ribose) polymerase activity and induce synthetic lethality in BRCA mutant cells
por: MAEDA, JUNKO, et al.
Publicado: (2014)

The Effect of Green and Black Tea Polyphenols on BRCA2 Deficient Chinese Hamster Cells by Synthetic Lethality through PARP Inhibition
por: Alqahtani, Shaherah, et al.
Publicado: (2019)

Data for induction of cytotoxic response by natural and novel quercetin glycosides
por: Haskins, Alexis H., et al.
Publicado: (2015)

Palmitoyl ascorbic acid 2-glucoside has the potential to protect mammalian cells from high-LET carbon-ion radiation
por: Haskins, Alexis H., et al.
Publicado: (2018)

The trans cell cycle effects of PARP inhibitors underlie their selectivity toward BRCA1/2-deficient cells
por: Simoneau, Antoine, et al.
Publicado: (2021)

Selective Killing of BRCA2-Deficient Ovarian Cancer Cells via MRE11 Blockade
por: Alblihy, Adel, et al.
Publicado: (2023)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
por: Yang, Shicheng, et al.
Publicado: (2023)

Cytotoxicity and Mutagenicity of Narrowband UVB to Mammalian Cells
por: Buglewicz, Dylan J., et al.
Publicado: (2020)

Design and evaluation of a novel flavonoid-based radioprotective agent utilizing monoglucosyl rutin
por: Aizawa, Yasushi, et al.
Publicado: (2018)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
por: Ragupathi, Ashwin, et al.
Publicado: (2023)

Autoimmune response to PARP and BRCA1/BRCA2 in cancer
por: Zhu, Qing, et al.
Publicado: (2015)

Evaluating the Genotoxic and Cytotoxic Effects of Thymidine Analogs, 5-Ethynyl-2′-Deoxyuridine and 5-Bromo-2′-Deoxyurdine to Mammalian Cells
por: Haskins, Jeremy S., et al.
Publicado: (2020)

PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors
por: Staniszewska, Anna D., et al.
Publicado: (2022)

In Silico Investigation of the Molecular Mechanism of PARP1 Inhibition for the Treatment of BRCA-Deficient Cancers
por: Yan, Fengqin, et al.
Publicado: (2023)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
por: Ding, Xia, et al.
Publicado: (2016)

Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
por: Kawanishi, Miki, et al.
Publicado: (2022)

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
por: Ding, Liya, et al.
Publicado: (2018)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
por: Du, Tingting, et al.
Publicado: (2022)

The synthetic lethal killing of RAD54B-deficient colorectal cancer cells by PARP1 inhibition is enhanced with SOD1 inhibition
por: McAndrew, Erin N., et al.
Publicado: (2016)

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
por: Yazinski, Stephanie A., et al.
Publicado: (2017)

OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells
por: Baquero, Juan Miguel, et al.
Publicado: (2022)

Consolidated BRCA1/2 Variant Interpretation by MH BRCA Correlates with Predicted PARP Inhibitor Efficacy Association by MH Guide
por: Hirotsu, Yosuke, et al.
Publicado: (2020)

Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells
por: Sullivan-Reed, Katherine, et al.
Publicado: (2018)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
por: Tacconi, Eliana MC, et al.
Publicado: (2019)

The role of PARP inhibitors in BRCA mutated pancreatic cancer
por: Chi, Jeffrey, et al.
Publicado: (2021)

Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
por: Keung, Man Yee, et al.
Publicado: (2020)

Phosphorylation of ribosomal protein S6 confers PARP inhibitor resistance in BRCA1-deficient cancers
por: Sun, Chong-kui, et al.
Publicado: (2014)

DNA Repair Deficient Chinese Hamster Ovary Cells Exhibiting Differential Sensitivity to Charged Particle Radiation under Aerobic and Hypoxic Conditions
por: Cartwright, Ian M., et al.
Publicado: (2018)

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
por: Barazas, Marco, et al.
Publicado: (2018)

β-Lapachone Selectively Kills Hepatocellular Carcinoma Cells by Targeting NQO1 to Induce Extensive DNA Damage and PARP1 Hyperactivation
por: Zhao, Wenxiu, et al.
Publicado: (2021)

Reduced PAK1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition
por: Cruz, Olga Villamar, et al.
Publicado: (2016)

Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells
por: Smith, Hannah L, et al.
Publicado: (2020)

Selective killing of p53-deficient cancer cells by SP600125
por: Jemaà, Mohamed, et al.
Publicado: (2012)

Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells
por: Clements, Kristen E, et al.
Publicado: (2018)

STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
por: Wang, Qiwei, et al.
Publicado: (2022)

Enhancing synthetic lethality of PARP-inhibitor and cisplatin in BRCA-proficient tumour cells with hyperthermia
por: Oei, Arlene L., et al.
Publicado: (2017)

COMPROMISED CDK1 ACTIVITY SENSITIZES BRCA-PROFICIENT CANCERS TO PARP INHIBITION
por: Johnson, Neil, et al.
Publicado: (2011)

The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells
por: Arun, Banu, et al.
Publicado: (2015)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_g8l4e16dl36vbd54rh9132qj1m